Browse communities
Browse communities
Presenting a webinar?

Medical Research

Community information
The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
  • Microbiological methods play a critical role in ensuring safety and efficacy of drugs and biologics. Most microbiological methods are described in compendia and do not need method validation. However, rapid microbiological methods and other alternate methods require full validation. Due to large inherent variability and complexity of microbiological methods, there are challenges in validation of such methods. This webinar will discuss, ways of performing validation of microbiological methods, with a view to achieving regulatory compliance.
  • In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • Visit this page to download our infographic:
    http://www.vitaminsinmotion.com/fileadmin/data/pdf/Infographics/Vitamine-E-_-Cognition-11.jpg

    In our aging society, Alzheimer’s type dementia is a major concern. The disease can have a devastating impact on quality of life, with patients relying on caregivers for standard daily living activities. Whether it is memory impairment, deterioration, confusion or anger suffered by patients, this highly disruptive neurological disease demands attention.

    Vitamin E is vital for neural function and its deficiency can lead to neurological dysfunction, causing problems with co-ordination, balance and speech. It also has an antioxidant function in the brain – as a free radical scavenger and constituent of neural membranes, preventing the oxidation of lipids and PUFAs.

    Now, recent studies have found that maintaining a high level of vitamin E results in marked improvements for mental health and can be linked individually with a decrease in the onset of Alzheimer’s type dementia.

    Join our webinar and hear our speakers Prof. Maurice Dyksen and DSM’s Dr. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E and its potential role in curbing the onset of Alzheimer’s disease.
  • In the present study, a genome-wide RNA interference screen was combined with an extensive biochemical analysis and quantitative proteomics to better understand the regulation of the heat-shock response (HSR) upon thermal stress. The usage of an endoribonuclease-prepared small interfering RNA (esiRNA) library represented a simple and efficient way to perform RNAi with minimal off-target effects. In the screening experiments novel positive and negative modulators of the stress response were identified, including proteins involved in chromatin remodeling, transcription, mRNA splicing, DNA damage repair, and proteolytic degradation. The diversity of the identified regulators suggests that induction and attenuation of the HSR integrate signals from different cellular pathways and are rather multi-factorial processes than single gene/protein events. The modulator proteins are localized in multiple cellular compartments with the majority having their primary location in the nucleus. A protein-protein interaction analysis revealed a HSR regulatory network, with chromatin modifiers and nuclear protein quality control components occupying hub positions. These observations are supported by quantitative proteomics experiments, which showed specific stress-induced reorganizations of the nuclear proteome, including the transient accumulation of chaperones and proteasomal subunits.
    Moreover, we found that the acetyltransferase EP300 controls the cellular level of activatable HSF1. This involves acetylation of HSF1 at multiple lysines not required for function and results in stabilization of HSF1 against proteasomal turnover. Acetylation of functionally critical lysines during stress serves to fine-tune HSF1 activation. Finally, the nuclear proteasome system functions in attenuating the stress response by degrading activated HSF1 in a manner linked with the clearance of misfolded proteins.
  • The way that physicians want and need to consume information is changing, almost to the point of being unrecognisable from the tried and tested methods of yesteryear, Working in conjunction with Ashfield Healthcare this event brings together Medical Futurist Dr Bertalan Meskó, Dr Partha Kar, Consultant Endocrinologist, Portsmouth Hospitals NHS Trust, with Ruth Herman and Nigel Campbell of Ashfield, which recently launched the Medical Education Future Forum and will be presenting insights from this unique programme.

    Taking place on the 21st May at 12.30 (UK), 13.30 (EU), 07.30 (E. US) and moderated by pharmaphorum's CEO Paul Tunnah, the debate will centre on three key questions,

    Why and how are physicians changing the way they receive information?
    What are the trends and technologies shaping the landscape of medical communication?
    What are the implications of this for pharma (with examples)?
  • Visit this page to download our infographic:
    http://www.vitaminsinmotion.com/fileadmin/data/pdf/Infographics/Vitamine-E-_-Cognition-11.jpg

    In our aging society, Alzheimer’s type dementia is a major concern. The disease can have a devastating impact on quality of life, with patients relying on caregivers for standard daily living activities. Whether it is memory impairment, deterioration, confusion or anger suffered by patients, this highly disruptive neurological disease demands attention.

    Vitamin E is vital for neural function and its deficiency can lead to neurological dysfunction, causing problems with co-ordination, balance and speech. It also has an antioxidant function in the brain – as a free radical scavenger and constituent of neural membranes, preventing the oxidation of lipids and PUFAs.

    Now, recent studies have found that maintaining a high level of vitamin E results in marked improvements for mental health and can be linked individually with a decrease in the onset of Alzheimer’s type dementia.

    Join our webinar and hear our speakers Prof. Maurice Dyksen and DSM’s Dr. Manfred Eggersdorfer and Jacob Bauly present their latest findings on vitamin E and its potential role in curbing the onset of Alzheimer’s disease.
  • Parents should be given full information on the benefits of human milk for their newborns, as well as the health consequences of not using human milk, and the risks and costs of formula feeding.
  • While cost is a primary "c" driving the adoption of object-based cloud solutions in the life sciences, compute, capacity, and collaboration may all be bigger incentives. In this webinar, we'll examine how to use an Avere Hybrid Cloud NAS infrastructure to gain big benefits in areas like genomics research, personalized medicine, drug discovery, imaging, and other data analysis applications.

    • Compute - Building production environments in the compute cloud without rewriting existing applications

    • Capacity - Modernizing storage archives and disaster recovery by adding object storage for durability while leveraging existing on-premises NAS

    • Collaboration - Using the cloud t o safely and securely share data globally

    • Cost - Using cloud to lower overall costs to keep pace with fast-growing demands of research initiatives
  • Originally launched in 2001, Enzyme Explorer was Sigma-Aldrich's first Web-based tool developed to provide customers with on-line technical resources to aid in their research and manufacturing applications. Since that time, Sigma scientists and curators have continually added content and new functionality.
    One example of the tools available is the Enzyme Explorer’s Assay Library. It features over 600 detailed procedures for measuring enzyme activity and related metabolites. The Library is the result of over ten years of in-house process development by Sigma-Aldrich scientists. In addition, we have recently upgraded the classical Nicholson Metabolic Pathway Chart. Now all metabolites, enzymes, and selected pathways are searchable and interactive.
    The Enzyme Explorer also provides easy access to the most extensive line of enzyme, proteins, substrate, inhibitor and cofactor related products in the industry.
    This webinar will give an overview of all the tools and content available and help users navigate to the content they need.
  • Originally launched in 2001, Enzyme Explorer was Sigma-Aldrich's first Web-based tool developed to provide customers with on-line technical resources to aid in their research and manufacturing applications. Since that time, Sigma scientists and curators have continually added content and new functionality.
    One example of the tools available is the Enzyme Explorer’s Assay Library. It features over 600 detailed procedures for measuring enzyme activity and related metabolites. The Library is the result of over ten years of in-house process development by Sigma-Aldrich scientists. In addition, we have recently upgraded the classical Nicholson Metabolic Pathway Chart. Now all metabolites, enzymes, and selected pathways are searchable and interactive.
    The Enzyme Explorer also provides easy access to the most extensive line of enzyme, proteins, substrate, inhibitor and cofactor related products in the industry.
    This webinar will give an overview of all the tools and content available and help users navigate to the content they need.
  • What is HIPAA? What information is protected by HIPAA? Do we have to sign Business Associate Agreements with our vendors? All of these questions and more answered on this BrightTALK exclusive webinar, 8 HIPAA FAQs for Businesses. Join Carlo Tapia, Product Marketing Manager at eFolder, as he takes you through commonly asked questions, an overview of HIPAA, the costs associated with HIPAA violations, and how to protect sensitive patient health information. Business influencers and IT admins will appreciate this 45-minute introduction to the stringent regulations of HIPAA.
  • The article considers the opportunities for risk based change in facility design through quality by design (QbD) and advances in PAT. It suggests that the inclusion of a mix of biopharmaceutical products alongside oral solid dose products could work based on a manufacturing dancefloor concept. Further that both upstream and downstream may be considered in a new light with the potential for in-process real-time testing and approval significantly reducing or withdrawing entirely the need for work-in-progress (WIP) inventory and quarantine storage needs as supply chain management processes integrate.
  • Complex treatment delivery techniques allowing faster and more accurate treatments are rapidly gaining clinical acceptance. These complex deliveries require a comprehensive approach to quality assurance that takes into account the types of treatments being delivered and the range of devices being used for delivery. The commonly used AAPM TG-142 report provides some guidance, but this shouldn’t be considered a stand-alone QA programme; it is a small piece in a comprehensive QA programme. A comprehensive QA programme requires equipment and devices, software, personnel, training, data recording, historical review tools, standard operating procedures, approval mechanisms, and an understanding of how the tests apply to your treatment system. Successfully implementing TG-142 requires more than simply conducting the tests listed in the tables; understanding the natural variation of processes, preparation and planning is also needed so that all the necessary aspects are considered to allow for safe delivery of complex treatment delivery techniques. Join Dr Moseley as he discusses the planning and decisions that are needed to be made so that you can succeed at implementing your TG-142 programme.
  • La malnutrición es un problema general a nivel mundial, ya que las personas no consumen el nivel suficiente de nutrientes esenciales. A su vez, la obesidad se ha convertido en una preocupación creciente porque se consumen demasiados alimentos para el nivel de actividad. A este ritmo, la sociedad actual no podrá cumplir con los objetivos de la Asamblea Mundial de la Salud (WHA) 2025 en materia de nutrición y es esencial que los programas de nutrición se desarrollen aún más para mejorar la situación nutricional. La fortificación de los alimentos es una manera efectiva de producir alimentos altamente nutritivos y combatir la malnutrición y así lograr un mejor desarrollo socioeconómico. La industria de alimentos, bebidas y suplemento dietario cumple una función clave en la promoción de la nutrición de la salud pública al desarrollar opciones nutritivas, saludables y asequibles para los consumidores.

    En este seminario web informativo, el experto independiente Alfonso Valenzuela Bonomo junto con Hector Cori de DSM, director de Nutrition Science & Advocacy LATAM, debatirán sobre la necesidad de la colaboración entre sectores (gobierno, organizaciones civiles y empresas) para combatir la malnutrición.
  • La malnutrición es un problema general a nivel mundial, ya que las personas no consumen el nivel suficiente de nutrientes esenciales. A su vez, la obesidad se ha convertido en una preocupación creciente porque se consumen demasiados alimentos para el nivel de actividad. A este ritmo, la sociedad actual no podrá cumplir con los objetivos de la Asamblea Mundial de la Salud (WHA) 2025 en materia de nutrición y es esencial que los programas de nutrición se desarrollen aún más para mejorar la situación nutricional. La fortificación de los alimentos es una manera efectiva de producir alimentos altamente nutritivos y combatir la malnutrición y así lograr un mejor desarrollo socioeconómico. La industria de alimentos, bebidas y suplemento dietario cumple una función clave en la promoción de la nutrición de la salud pública al desarrollar opciones nutritivas, saludables y asequibles para los consumidores.

    En este seminario web informativo, el experto independiente Alfonso Valenzuela Bonomo junto con Hector Cori de DSM, director de Nutrition Science & Advocacy LATAM, debatirán sobre la necesidad de la colaboración entre sectores (gobierno, organizaciones civiles y empresas) para combatir la malnutrición.
  • This webinar will introduce the history, theory, basic techniques, and potential pit-falls of mammalian cell culture. It is designed for students and new lab technicians, as well as bench scientists interested in updating their techniques or knowledge in the field.

    Topics to be discussed include:
    • History and practical theories of cell culture and its impact on today’s science
    • The requirements needed to set up a cell culture laboratory
    • Challenges when performing mammalian cell culture and how to overcome them

    About our Presenter:
    Dr. Mark Rothenberg graduated from Emory University with his Ph.D. in Cell and Developmental Biology. Over the past 25 years, Mark has held positions in both academia and industry where he has developed an expertise in the areas of assay development and cell culture. He currently holds the position of Manager Scientific Training and Education with Corning Life Sciences.
  • Gap junctions (GJs) are large aggregates of intercellular channels that facilitate the diffusion of small molecules and ions between two interacting cells. GJ intercellular channels are formed through the interaction of two half-channels, called hemichannels, composed of oligomerized connexin protein subunits. Both GJs and hemichannels have numerous important physiological and pathological roles in tissue functions including propagation of the action potential in the heart, tumor growth and metastasis, the inflammatory response and adaptive immunity, wound healing, and electrical synaptic transmission in the central nervous system. The most widely expressed connexin isoform is Cx43, and its regulation in the abovementioned processes has been a major focus of GJ research. Over the past two decades protein-protein interaction with the cytoplasmic carboxyl terminus of Cx43 has come to the fore as an endogenous mechanism for controlling the GJ life cycle, channel gating, and channel-independent functions. We have used the Duolink proximity ligation assay (PLA) as a technique to study protein interactions with Cx43 in cultured cells. Two unique aspects of the technology – specifically, subcellular localization and the binary nature of the labeling – in combination with standard immunofluorescent confocal imaging techniques have yielded unexpected insights into GJ ultrastructure, action potential conduction, and the mechanistic regulation of Cx43 trafficking and hemichannel accretion to GJ plaques. In this context, the practical application of, appropriate controls for, and interpretation of Duolink PLAs will be explicated.
  • Gap junctions (GJs) are large aggregates of intercellular channels that facilitate the diffusion of small molecules and ions between two interacting cells. GJ intercellular channels are formed through the interaction of two half-channels, called hemichannels, composed of oligomerized connexin protein subunits. Both GJs and hemichannels have numerous important physiological and pathological roles in tissue functions including propagation of the action potential in the heart, tumor growth and metastasis, the inflammatory response and adaptive immunity, wound healing, and electrical synaptic transmission in the central nervous system. The most widely expressed connexin isoform is Cx43, and its regulation in the abovementioned processes has been a major focus of GJ research. Over the past two decades protein-protein interaction with the cytoplasmic carboxyl terminus of Cx43 has come to the fore as an endogenous mechanism for controlling the GJ life cycle, channel gating, and channel-independent functions. We have used the Duolink proximity ligation assay (PLA) as a technique to study protein interactions with Cx43 in cultured cells. Two unique aspects of the technology – specifically, subcellular localization and the binary nature of the labeling – in combination with standard immunofluorescent confocal imaging techniques have yielded unexpected insights into GJ ultrastructure, action potential conduction, and the mechanistic regulation of Cx43 trafficking and hemichannel accretion to GJ plaques. In this context, the practical application of, appropriate controls for, and interpretation of Duolink PLAs will be explicated.
  • Join us for a free webinar on Wednesday 22 April to hear author Professor Malcolm Sperrin talk about his latest book Scientific Basis of the Royal College of Radiologists Fellowship - Illustrated questions and answers.

    During this free live webinar the author will show sample questions and detailed solutions, there will also be a live Q&A session at the end.

    This webinar is recommended listening for anyone training for radiological board exams, graduate students in medical physics, clinicians and technologists. It is also suitable for other board exams or professional development.
  • The webinar will give an overview about general drug delivery requirements for paediatric drug products and current discussions concerning the EU and US regulations.
    In-depth Case Studies featuring Patient-centric Paediatric formulations, will also be presented.
  • Join us on April 16, 2015 @ 7:00PM (EST) for Creating a Positive Patient-Provider Relationship, led by ICA Board member, Joy Selak, PhD, and her healthcare provider, Steven S. Overman, MD, MPH. Drs. Selak and Overman together wrote a book, You Don’t LOOK Sick!: Living Well with Invisible Chronic Illness, about their shared experience. This webinar will focus on how to find effective, supportive care and creating a positive patient-provider relationship.
  • Your environmental testing laboratory is facing harsher EPA emission regulations and competitive sample prices, making is essential to keep up on new technology. The BUCHI Syncore® Parallel Concentrator not only recovers > 95% of solvent but it also provides a crucial competitive advantage. Join this webinar to learn how today’s top environmental testing laboratories are staying ahead of their competition with the implementation of the Syncore® Analyst.
  • Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election.

    With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines:

    With this scenario in mind pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.

    Angela McFarlane, Senior principal IMS Health Local Market Access, Anthony Grosso, Principal Pharmacist at the National Hospital for Neurology and Neurosurgery and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum's Paul Tunnah to deliver an accurate analysis and frontline insight as to the already complex roadmap for access is about to change again.

    This one hour event will include analysis of informed predictions which include:

    The NICE HTA criteria will get tougher post end to end review (IMMTreV)
    NICE and the NHS England will join forces to streamline access pre/post NICE
    Risk at local level will be shifted to Providers under the new marginal tariff arrangements; which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
    Provider baselines will take the strain of innovation - the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines

    How can industry prepare for these changes in what is already a tough and complex environment?
  • Although there are many techniques to study epigenetic marks such as DNA- and histone-methylation, on a genomic scale, there exists a need in the field to visualize these epigenetic marks at a single genomic locus in individual cells. Such an application requires a highly sensitive detection method. With this aim, a protocol was developed to perform in-situ hybridization followed by proximity ligation assay (a.k.a. Duolink®) and cell imaging to visualize DNA-methylation (5meC) on the SEPTIN9 promoter. SEPTIN9 promoter methylation is a known biomarker for colon cancer. After optimizing cross-linking, cell permeabilization and chromatin accessibility, the genomic specificity was ascertained by hybridizing with a pool of biotinylated-oligo probes that target the CpG islands in the human SEPTIN9 promoter. The Duolink assay was performed using anti-biotin and anti-5meC antibodies, corresponding proximity ligation assay probes, and Far Red detection reagents.
    Imaging by fluorescent microscopy revealed two red punctate spots in metastatic prostate cancer DU145 cells (diploid for chromosome 17 – location of SEPTIN9 gene) and three red spots in colon cancer SW480 cells (triploid for Chr17). No signal was observed in normal cells (BJ) or with non-specific oligo probes (LacZ). A decrease in Duolink signal was observed when the DU145 cells were treated with 5-AzaC, a drug known to block DNA-methylation. This proof of concept study will be extended to frozen and formalin fixed paraffin embedded human cancer tissue samples.
    Fluorescent imaging data will also be presented from a Duolink assay to monitor the interaction of EZH2 histone methyltransferase with the H3K27me3 epigenetic mark in prostate cancer (DU145) cells. Reduction in the Duolink signal demonstrated inhibition of EZH2 activity by the small molecule inhibitors SAHA and GSK343.